Home/Filings/4/0001062993-24-003168
4//SEC Filing

Smith Thomas B 4

Accession 0001062993-24-003168

CIK 0001267565other

Filed

Feb 13, 7:00 PM ET

Accepted

Feb 14, 4:14 PM ET

Size

10.2 KB

Accession

0001062993-24-003168

Insider Transaction Report

Form 4
Period: 2024-02-12
Smith Thomas B
EVP and Chief Medical Officer
Transactions
  • Award

    Common Stock

    2024-02-12+30,80062,980 total
  • Award

    Common Stock

    2024-02-12+4,62367,603 total
  • Tax Payment

    Common Stock

    2024-02-12$33.70/sh1,899$63,99665,704 total
  • Tax Payment

    Common Stock

    2024-02-12$33.70/sh1,300$43,81064,404 total
Footnotes (5)
  • [F1]Reflects the grant of restricted stock units ("RSUs"). Each RSU represents a contingent right to receive one share of the Issuer's common stock. One-third (33%) of the RSUs shall vest on February 10, 2025, with the balance of the RSUs vesting in equal annual installments over the following two-year period, subject to the Reporting Person's continued service with the Issuer. The RSUs will be settled on each applicable vesting date in shares of the Issuer's common stock.
  • [F2]Includes 442 and 553 shares acquired on each of July 21, 2023 and January 19, 2024, respectively, under the Issuer's employee stock purchase plan.
  • [F3]Effective February 12, 2024, the Compensation Committee of the Board of Directors of the Issuer determined that performance-vesting criteria were met with regard to an aggregate of 4,623 performance share units ("PSUs") granted in the Issuer's prior fiscal year.
  • [F4]Shares withheld by the Issuer to satisfy applicable withholding taxes upon the vesting of RSUs.
  • [F5]Shares withheld by the Issuer to satisfy applicable withholding taxes upon the vesting of PSUs.

Issuer

COLLEGIUM PHARMACEUTICAL, INC

CIK 0001267565

Entity typeother

Related Parties

1
  • filerCIK 0001748462

Filing Metadata

Form type
4
Filed
Feb 13, 7:00 PM ET
Accepted
Feb 14, 4:14 PM ET
Size
10.2 KB